Brind.

Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.

1 report, 1 independent Updated Sep 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Donald Trump Vertex Pharmaceuticals

Keep exploring

The entities involved

Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump holds influence in the Republican Party while tasking JD Vance with resolving the Iran issue and considering him for administration roles.18:43
- Schumer criticizes Trump's leadership and policy as Democrats refuse to support funding for Iran during Senate debates.18:42
Vertex Pharmaceuticals
American pharmaceutical company
- Multiple financial firms, including Americana Partners and Summit Global Investments, adjusted their holdings in Vertex Pharmaceuticals on November 4, 2026.12:13
- Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.Tue 17:13

Related events

Tariffs implemented in April 2025 caused a significant market tailspin.Jun 7

Coverage

Newest first; wire copies grouped

Sep 3Insider MonkeyHere’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor let